MaxCyte Minutes Newsletter – Q3 2023

CRISPR Electroporation of T Cells Improves Treatment in Patients with Refractory Cancer

Welcome to the latest edition of our Quarterly MaxCyte Minutes Newsletter. As your partner in scientific advancement, we are thrilled to offer you a compilation of news, events, and technical insights. We’re excited to accelerate your research journey from concept to commercialization.

We are privileged to join you on your transformative journey, unlocking the potential of cells to change lives. Thank you for choosing MaxCyte® as your partner in pushing boundaries and bringing new therapies to patients.


We are excited to announce two new partnerships.


MaxCyte Signs Strategic Platform License with Vittoria Biotherapeutics to Support viTToria’s Senza5™ Technology.


We’re excited to announce a new partnership with Vittoria Biotherapeutics, a leading-edge, gene-edited cell therapeutics company. MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support viTToria’s Senza5™ technology to improve the clinical utility of T-cell therapies.

“Through this collaboration with viTToria, we aim to support their efforts to enhance efficacy and improve safety of T-cell therapies.”
– MaxCyte CEO Doug Doerfler.

MaxCyte and Prime Medicine, Inc., Sign Strategic Platform License to Advance Next-Generation Gene Editing Therapies.

MaxCyte is pleased to announce that we are partnering with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies. Prime Medicine will use our Flow Electroporation® technology and ExPERT™ platform to develop their next-generation gene therapies for patients.

“We are pleased to partner with Prime Medicine and support their breakthrough gene editing technology. The company’s innovative vision and transformative scientific approach are clearly reshaping how genetic diseases are studied and ultimately will be treated.”
– MaxCyte CEO Doug Doerfler.


Accelerate biotherapeutic development using transient expression to produce multi-grams of protein.

Discover how to streamline your therapeutic development with Flow Electroporation®. MaxCyte’s technology can expedite the development and manufacturing of biotherapeutics, including monoclonal antibodies and vaccines, in a wide range of cell types.

Learn how we equip you with the right tools, support and regulatory expertise to light the way on your journey to discovery.

FIND OUT MORE VLx and scientist



Reduce Cell Therapy Manufacturing Risk with MaxCyte.

Cell therapy is rapidly advancing with increasingly sophisticated cell engineering strategies. This complexity introduces a variety of challenges to the manufacturing process, increasing the risk of failure. This FastFacts video and poster will demonstrate how MaxCyte electroporation can address key risk factors during cell therapy manufacturing.



Webinar: CHOp your protein production timelines.

If you missed our CHOp your protein production timelines webinar, you can now view it on-demand! Learn how to drive your biologics development forward by leveraging MaxCyte’s Flow Electroporation. This flexible, scalable technology enables alternative strategies for the rapid development of high-yield stable cell lines and can deliver gram-scale transient protein production within two weeks.

VIEW WEBINAR webinar CHOp your protein production timelines


Andy Lamb

Interview with Andy Lamb.

In this issue, Andy Lamb, Senior Director of Global Strategic Partnerships, discusses his experience in commercial sales within the healthcare and biotechnology industries. Here, he shares why he is passionate about working at MaxCyte, “We are literally one step removed from dosing patients; being able to have such an impact on their lives is why I get out of bed every day and come to work. The treatments being developed on the MaxCyte system are helping to extend the lives of patients and potentially cure them altogether, giving them more time to spend with their families. I am proud to work here because MaxCyte does it right – putting patients first. They always have and always will because of our strong leadership and dedicated team members.”



NK2023 – Society for Natural Immunity Sept 26-29, Oslo, Norway

Cell & Gene Meeting on the Mesa – Oct 11 – 12, Carlsbad, CA

ESGCT – Oct 24 – 27, Brussels



Leave a Comment